

BAB 5

SIMPULAN

5.1. Simpulan

PVP K-30 sebagai bahan pengikat tablet dan xanthan gum sebagai bahan penghancur tablet maupun interaksinya berpengaruh secara signifikan terhadap sifat mutu fisik dan disolusi propranolol HCl dalam sediaan tablet sublingual. PVP K-30 meningkatkan kekerasan tablet, menurunkan kerapuhan tablet, memperlambat waktu hancur tablet, dan menurunkan jumlah obat yang terlarut dalam waktu 15 menit. Sedangkan xanthan gum menurunkan kekerasan tablet, meningkatkan kerapuhan tablet, mempercepat waktu hancur tablet, dan meningkatkan jumlah obat yang terlarut dalam waktu 15 menit. Interaksi dari PVP K-30 dan xanthan gum memberikan pengaruh meningkatkan kekerasan tablet, meningkatkan kerapuhan tablet, memperlambat waktu hancur tablet, dan menurunkan jumlah obat yang terlarut dalam waktu 15 menit.

Formula optimum tablet sublingual dapat diperoleh dengan kombinasi PVP K-30 1% dan xanthan gum 5% dengan hasil teoritis, kekerasan tablet sebesar 4,72 kp, kerapuhan tablet sebesar 0,62%, waktu hancur tablet sebesar 3,33 menit, dan persen disolusi tablet sebesar 93,44%.

5.2. Alur Penelitian Selanjutnya

Sebaiknya dilakukan penelitian lebih lanjut mengenai parameter farmakokinetik sediaan tablet sublingual propranolol HCl dan dicari korelasi in vivo-in vitro, yang diharapkan memberikan hasil yang baik.

DAFTAR PUSTAKA

- Anonim, 1995. **Farmakope Indonesia**, ed. IV. Departemen Kesehatan Republik Indonesia, Jakarta, hal. 4, 710, 999-1000, 1086-1087
- Ansel, .C.H, 1989. **Pengantar Bentuk Sediaan Farmasi**. (Ibrahim, F., penerjemah), 4th ed., UI Press. Jakarta, pp 118-120, 144, 148, 247-299
- Banakar, U.V., 1992. **Pharmaceutical Dissolution Testing**, Marcel Dekker, Inc., New York, pp. 19-26, 322-330
- Banker, G.S and Anderson, N.R., 1986. Tablet In: Lachman, L., Lieberman. H.A., Kanig, J.L., (Eds.), **The Teory and Practice of Industrial Pharmacy**, 3rd ed., Lea and Febiger, Philadelphia, pp. 293-317
- Bele, M. H., and Derle, D. V., 2002. **Analysis of Patents Pertaining to Superdisintegrants used in Tablet Manufacturing**, Journal of Intellectual Property Rights, Vol 13, 601-604
- Bolourchian, N., Naghmeh, H., Seyed, M. F., Bijan, S., 2009. Development and Optimization of a Sublingual Tablet Formulation for Physostigmine Salicylate, **Acta Pharm.**, 59, 301-312
- Bolton, S., 1990, **Pharmaceutical Statistics, Practical and Clinical Application**, Marcel Dekker, New York, 309-319
- Gibson, M., 2009. *Pharmaceutical Preformulation and Formulation A Practical Guide from Candidate Drug Selection to Commercial Dosage Form*, informa Healthcare, New York, 420
- Gordon, R. E., Ronsanske, T. W., Fonner, D. E., Anderson, N. R., Banker, G. B., 1990. Granulation Technology, in: **Pharmaceutical Dossage Forms: Tablets**, Vol. 3, 2nd edition, Lachman, L., Lieberman, H. A., Marcell Dekker, Inc., New York, 254-268
- Green, J. M., 1996. **A Practical Guide to Analysis Method Validation**, Analytical Chemistry, 23; 305-309

- Kellaway, I. W., Ponchel. G., and Duchene., 2003. **Oral Mucosal Drug Delivery**, Marcel Dekker, Inc., New York, 349-353
- Kibbe, A. H., 2000, **Handbook of Pharmaceutical Exipients**, 3rd edition, American Pharmaceutical Association, Washington DC, 220-221, 401-404
- Lieberman, H.A., Lachman, L., Schwatz, J.B., 1989. **Tablet Formulation and Design, Pharmaceutical Dosage Forms: Tablet**. Vol. 7, 2nd edition. Marcell Dekker, New York, hal. 258-326
- Martin, A., Swarbrick, J., Cammarata, A., 1993. **Farmasi Fisik: Dasar – Dasar Kimia Fisik dalam Ilmu Farmasetik**. (Yoshita, penerjemah). Universitas Indonesia Press, Jakarta, hal. 845-847
- Robinson, R. J., and B. Li., 2005. Preclinical Assessment of Oral Mucosal Drug Delivery Systems, in: **Drug Delivery to the Oral Cavity Molecules to Market**, Ghosh, T. K, and William, R. P (Eds.), CRC Press, United States of America, 43-44
- Rowe, R.C., Sheskey, J.P., Weller, J.P., 2003. **Handbook of Pharmaceutical Excipients 4th Edition**, Pharmaceutical Press, London, pp. 324-325, 354, 355, 508-508, 641
- Schum, C. D., and Wallach, D., 2006. **Evaluating Goodness-of-Fit in Comparison of Models to Data**, University of Pittsburgh, Pittsburgh, 7-33
- Setiawati, A., dan Bustami, S. Z., 1995. Antihipertensi, in: Ganiswarna, S. G., (Ed), **Farmakologi dan Terapi**, edisi 4, FK-UI, Jakarta, 86-87, 326-327
- Shargel, L. and Yu, B.C., 1999. **Applied Biopharmaceutics Technology**, 4th ed., McGraw-Hill, London, pp. 169-201
- United States Pharmacopoeia XXVIII**, 2005. The United States Pharmacopoeial Convention, Inc., Philadelphia, 1661

Vogelpoel, H., Welink, J., Amidon, G. E., H.E., Midha., K.K., Olling, M., Shah, V. P., and Barends, D. M., 2004. Biowaiver monographs for Immediate Release Solid Oral Dossage Forms Based on Biopharmaceutics Classification System (BSC) Literature Data: Verapamil Hydrochliride, propranolol Hydrochloride, and atenolol, **J. Pharm Sci.**, 93(8), 1945-1951

Wagner, J.G., 1971. **Biopharmaceutics and Relevant Pharmacokinetic**, Drug Intelligence Publications, Illinois, pp. 64-110

Wells, J.L., 1993. **Pharmaceutical Preformulations: The Physicochemical Properties of Drug Substance**. Ellis Horwood Limited, London, pp.209-214

Winek, C. L., Wahba, W. W., and Balzer, T. W., 2001. **Winek's Drug and Chemical Blood-Level Data.**, 1-17

